BiotechTube

ASP9831 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Alcoholic Steatohepatitis

Conditions

Non-Alcoholic Steatohepatitis

Trial Timeline

Apr 1, 2008 → Oct 1, 2010

NCT ID
NCT00668070

About ASP9831 + Placebo

ASP9831 + Placebo is a phase 2 stage product being developed by Astellas Pharma for Non-Alcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00668070. Target conditions include Non-Alcoholic Steatohepatitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00668070Phase 2Completed

Competing Products

20 competing products in Non-Alcoholic Steatohepatitis

See all competitors
ProductCompanyStageHype Score
IVA337 + IVA337 + PlaceboInventivaPhase 2
47
GODEX + PlaceboCelltrionPhase 3
77
AZD9550 + AZD9550 + PlaceboAstraZenecaPhase 1
33
AZD2693AstraZenecaPhase 1
33
placebo + Omega-3 carboxylic acids + Dapagliflozin + PlaceboAstraZenecaPhase 2
52
AZD4831AstraZenecaPhase 2
52
AZ compoundAstraZenecaPhase 2
52
cotadutide solution for injectionAstraZenecaPhase 1
33
Cotadutide + Cotadutide-placebo + Moxifloxacin + Moxifloxacin-placeboAstraZenecaPhase 1
33
AZD4076 + PlaceboAstraZenecaPhase 1
33
Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + PlaceboAstraZenecaPhase 2
52
Cotadutide + PlaceboAstraZenecaPhase 2
52
AZD7503 InterventionAstraZenecaPhase 1
33
Efinopegdutide + Semaglutide + PlaceboMerckPhase 2
52
MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochlorideMerckPhase 1
33
EfinopegdutideMerckPhase 1
33
LIK066 + PlaceboNovartisPhase 2
52
Tropifexor (LJN452) + Cenicriviroc (CVC)NovartisPhase 2
52
LYS006 + TropifexorNovartisPhase 2
52
LMB763 + PlaceboNovartisPhase 2
52

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85